JAMA

11/28/2025

Pickleball is the fastest growing sport in the US, but with its rise in popularity has come a corresponding increase in injuries, especially among older adults.

JAMA reported on the latest research surrounding and its related injuries.

📽️ Watch the video and read the full article: https://ja.ma/4ofHKAM

11/27/2025

Postpartum prescription of -1RAs in Denmark increased between 2018 and 2024, with accounting for most prescriptions since 2023. Most users had or , and only 23% had a diagnosis.

https://ja.ma/4oWW7v3

11/27/2025

💬 Editorial: A study in JAMA demonstrates that most new-onset atrial fibrillation (AF) episodes after cardiac surgery are brief and resolve within 30 days.

These findings support the concept that postoperative AF is reversible and suggest long-term anticoagulation should be the exception rather than the norm for these patients, pending further evidence.

https://ja.ma/4py6aqn

11/27/2025

Among patients with insertable cardiac monitors after CABG, the cumulative 1-year incidence of new-onset AF was 48%, yet median AF burden after 30 days was nearly zero.

https://ja.ma/49Hc1oz

11/27/2025

Postpartum prescription of -1RAs in Denmark increased between 2018 and 2024, with accounting for most prescriptions since 2023. Most users had or , and only 23% had a diagnosis.

https://ja.ma/4pvLOhl

11/27/2025

-1 receptor agonist exposure with discontinuation before or during early was associated with greater gestational weight gain and increased risk of preterm delivery, gestational , and hypertensive disorders.

https://ja.ma/3XPqgQT

11/26/2025

Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use.

Kevin Hill, MD, MHS, of Harvard Medical School joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence about the therapeutic use of cannabis and cannabinoids in adults, potential harms, and evidence-based clinical guidance.

🎧 Listen now:

Clinicians should weigh benefits against risks when engaging patients in informed discussions about cannabis or cannabinoid use. Kevin Hill, MD, MHS, of Harvard Medical School joins JAMA Senior Editor Karen Lasser, MD, MPH, to discuss the current evidence about the therapeutic use of cannabis and ca...

11/26/2025

Methamphetamine (sometimes called m**h, ice, speed, or crystal) is a highly addictive stimulant.

In 2019, there were 15 489 m**hamphetamine overdose deaths in the US, and slightly more than half of these deaths also involved opioids such as fentanyl.

📝 This JAMA Patient Page describes the acute and long-term effects of m**hamphetamine use and types of treatments, general medical care, and harm reduction strategies for people with m**hamphetamine use disorder.

https://ja.ma/4ojXWRE

11/26/2025

On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning -1 therapy and adults with .

Register for the webinar: https://ja.ma/4olWAWG

11/26/2025

From 2012 to 2023, the proportion of first-time PWID treatment admissions involving m**hamphetamine injection, with or without opioids, more than doubled, even as overall admissions declined.

Social and structural factors, such as increased m**hamphetamine availability, likely contributed to these trends.

https://ja.ma/48nMjmV

11/26/2025

Federal loan use among US medical students increased from 2008 to 2020 as tuition rose 38%. The One Big Beautiful Bill Act (OBBBA) eliminates Graduate PLUS Loans, institutes borrowing caps, and reduces repayment program generosity.

These restrictions are expected to disproportionately affect low-income and out-of-state students, and may lead to greater reliance on private loans, reduced interest in primary care, and less diversity in the physician workforce.



https://ja.ma/4omdCE7

11/26/2025

Approximately 27% of adults in the US and Canada report having ever used for medical purposes. An estimated 10.5% of the US population reports using cannabidiol (CBD), a chemical compound extracted from cannabis that does not have psychoactive effects, for therapeutic purposes.

This Review summarizes current evidence about the therapeutic use of cannabis and cannabinoids in adults, potential harms, and evidence-based clinical guidance, including pretreatment screening and addressing preexisting cannabis use in clinical settings.

https://ja.ma/48zH84i